<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01227772</url>
  </required_header>
  <id_info>
    <org_study_id>GA04/26/10</org_study_id>
    <nct_id>NCT01227772</nct_id>
  </id_info>
  <brief_title>Study of OTSGC-A24 Vaccine in Advanced Gastric Cancer</brief_title>
  <official_title>A Phase I/IIa Study of OTSGC-A24 Vaccine in Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National University Hospital, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wakayama Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National University Hospital, Singapore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Active vaccination with tumor specific antigens and VEGFR1 HLA-A24 epitopes can improve&#xD;
      survival of patients with advanced Gastric Cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although palliative chemotherapy improved the outcome of patients with advanced Gastric&#xD;
      Cancer, the prognosis for this group of patients remains poor. Tumor specific antigens and&#xD;
      angiogenesis pathway are potential targets for immunotherapy. A cocktail of peptide vaccines&#xD;
      is selected to overcome gastric cancer's heterogeneous and enhance the anti-tumor effect.&#xD;
      Five HLA-A*2402-binding peptide vaccines derived from tumor specific antigens and VEGFR1 are&#xD;
      chosen based on the frequencies of their expressions in gastric cancer and the ability to&#xD;
      induce specific cytotoxic T-lymphocytes. In preclinical model, both down regulation these&#xD;
      targets with siRNA and active vaccination resulted in tumor regression. The purpose of the&#xD;
      study is to evaluate the safety and optimal dosing schedule of a cancer vaccine cocktail,&#xD;
      OTSGC-A24 targeting novel specific tumor antigens FOXM1, DEPDC1, KIF20A, URLC10 and VEGFR1 in&#xD;
      advanced gastric cancer patients with HLA-2402 haplotype.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety of OTSGC-24</measure>
    <time_frame>within 4 weeks of treatment</time_frame>
    <description>Dose limiting toxicity will be evaluated during the first 4 weeks of treatment. If in the unlikely event that DLT is observed in 1 of the 3 subjects, an additional 3 subjects will be enrolled at the same dose level. If DLT is observed in 2 of the 6 subjects, subsequent cohorts will be treated at 0.5 mg.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Optimal dosing schedule</measure>
    <time_frame>1 year</time_frame>
    <description>In each cohort, OTSGC-A24 (~1 mg) will be administered subcutaneously at 3-weekly (cohort 1), 2-weekly (cohort 2) and weekly (cohort 3) interval. Treatment may continue until the subject experiences confirmed disease progression or unacceptable toxicity, withdraws consent, or requires treatment with another therapeutic modality.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Induction of specific cytotoxic T-lymphocyte (CTL) response</measure>
    <time_frame>after 4 weeks and 12 weeks of vaccination</time_frame>
    <description>Up to 10 patients per cohort will be recruited in the cohort or cohorts with the highest specific CTL induction rate to define the optimal dosing schedule for OTSGC-A24.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">23</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Weekly Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The gastric cancer vaccine (OTSGC-A24) will be administered at a dose of 1 mg once a week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2-weekly cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The gastric cancer vaccine (OTSGC-A24) will be administered at the dose of 1 mg every 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3-weekly cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The gastric cancer vaccine (OTSGC-A24)will be administered at 1 mg very 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>OTSGC-A24</intervention_name>
    <description>OTSGC-A24 administered at 1 mg in weekly, 2-weekly, and 3-weekly cohorts.</description>
    <arm_group_label>2-weekly cohort</arm_group_label>
    <arm_group_label>3-weekly cohort</arm_group_label>
    <arm_group_label>Weekly Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have histologically or cytologically confirmed inoperable or metastatic&#xD;
             adenocarcinoma of the stomach or lower third of the oesophagus refractory or&#xD;
             intolerable to standard therapy.&#xD;
&#xD;
          -  Patients must have measurable or evaluable disease.&#xD;
&#xD;
          -  Age &gt;= 201years&#xD;
&#xD;
          -  ECOG performance status of 0 to 2&#xD;
&#xD;
          -  Life expectancy at least 3 months&#xD;
&#xD;
          -  Patients must have normal organ and marrow function as defined below:&#xD;
&#xD;
          -  absolute neutrophil count &gt;=1,500/mcL&#xD;
&#xD;
          -  platelets &gt;=100,000/mcL&#xD;
&#xD;
          -  total bilirubin within normal institutional limits&#xD;
&#xD;
          -  AST(SGOT)/ALT(SGPT) &lt;=2.5 X institutional upper limit of&#xD;
&#xD;
          -  Normal creatinine within normal institutional limits&#xD;
&#xD;
          -  Patients must be HLA-A*2402&#xD;
&#xD;
          -  Patients must have recover from all reversible treatment toxicity from prior&#xD;
             chemotherapy, radiotherapy or surgery.&#xD;
&#xD;
          -  The effects of OTSGC-A24 on the developing human fetus at the recommended therapeutic&#xD;
             dose are unknown. For this reason, women of child-bearing potential and men must agree&#xD;
             to use adequate contraception (hormonal or barrier method of birth control;&#xD;
             abstinence) prior to study entry and for the duration of study participation. Should a&#xD;
             woman become pregnant or suspect she is pregnant while participating in this study,&#xD;
             she should inform her treating physician immediately.&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients receiving any other investigational agents.&#xD;
&#xD;
          -  History of significant gastrointestinal bleeding that required intervention within the&#xD;
             prior 1 month is ineligible; inherited bleeding diathesis or coagulopathy.&#xD;
&#xD;
          -  Serious non healing wound and peptic ulcer disease&#xD;
&#xD;
          -  Previous history of intestinal perforation&#xD;
&#xD;
          -  Invasive procedures defined as follows (Insertion of a vascular access device is not&#xD;
             considered major/minor surgery):&#xD;
&#xD;
          -  Major surgical procedure, open biopsy or significant traumatic injury =28 days prior&#xD;
             to -registration&#xD;
&#xD;
          -  Anticipation of need for major surgical procedures during the course of the study&#xD;
&#xD;
          -  Core biopsy &lt;=7 days&#xD;
&#xD;
          -  Minor surgery &lt;=2 weeks&#xD;
&#xD;
          -  Symptomatic CNS metastasis&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, uncontrolled hypertension (systolic &gt;150 mmHg and/or diastolic &gt;100 mmHg),&#xD;
             symptomatic congestive heart failure, unstable angina pectoris, myocardial&#xD;
             infarction/cerebrovascular event (&lt;=6 months prior to study entry), cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements, long term systemic immunosuppressant or corticosteroid.&#xD;
&#xD;
          -  Women who are breast-feeding or pregnant are excluded from this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Peng Yong, MRCP, MB ChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>National University Hospital, Singapore</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wakayama Medical University Hospital</name>
      <address>
        <city>Wakayama</city>
        <zip>641-8509</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
  </location_countries>
  <reference>
    <citation>Ajani JA. Evolving chemotherapy for advanced gastric cancer. Oncologist. 2005;10 Suppl 3:49-58. Review.</citation>
    <PMID>16368871</PMID>
  </reference>
  <reference>
    <citation>Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006 Jun 20;24(18):2903-9. Review.</citation>
    <PMID>16782930</PMID>
  </reference>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>October 21, 2010</study_first_submitted>
  <study_first_submitted_qc>October 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2010</study_first_posted>
  <last_update_submitted>June 21, 2016</last_update_submitted>
  <last_update_submitted_qc>June 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gastric cancer vaccine</keyword>
  <keyword>OTSGC-A24</keyword>
  <keyword>A Phase I/IIa study</keyword>
  <keyword>HLA-A24-positive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

